Over 8000 combinations of four of five antibiotics have been demonstrated to be more effective than previously thought, according to new research.
We speak to infectious diseases specialist, Ellie Goldstein (Santa Monica, CA, USA), about his recent publication on real world data and the challenges facing drug-resistant infections.
Clinical trial data has proved a novel, short therapy more effective and safe for the treatment of latent tuberculosis than the standard therapy in both adults and children.
Another big pharmaceutical is retreating from the development of new antibiotics, highlighting concerns around the challenges facing this market.
Antibiotic effectiveness can be restored if utilized in the correct combination with each other, non-antibiotic adjuvants or even food additives.
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
An isolate of colistin-heteroresistant, carbapenem-resistant, hypervirulent/hypermucoviscous Klebsiella pneumoniae has been identified in the USA.
A study presented at ASCO this weekend has suggested that antibiotic use greatly reduces the progression-free survival and overall survival of cancer patients receiving immunotherapy.
The UK government will commit more than £30 million towards funding research against antimicrobial resistance.
The Global Antibiotic Research & Development Partnership (GARDP) – an interview with Jean-Pierre Paccaud
In our latest interview, we spoke to Jean-Pierre Paccaud, Director of Business Development & Corporate Strategy at GARDP, about the drug developer’s model and his thoughts on the wider field.